



## Be aware of the X: *BCOR* mutations in myeloid neoplasms

by Guillermo Ramil, Marta Pratcorona, and Josep F. Nomdedeu

Received: January 17, 2024.

Accepted: January 26, 2024.

Citation: Guillermo Ramil, Marta Pratcorona, and Josep F. Nomdedeu.

Be aware of the X: *BCOR* mutations in myeloid neoplasms.

*Haematologica*. 2024 Feb 8. doi: 10.3324/haematol.2023.284748 [Epub ahead of print]

### *Publisher's Disclaimer.*

*E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication.*

*E-publishing of this PDF file has been approved by the authors. After having E-published Ahead of Print, manuscripts will then undergo technical and English editing, typesetting, proof correction and be presented for the authors' final approval; the final version of the manuscript will then appear in a regular issue of the journal. All legal disclaimers that apply to the journal also pertain to this production process.*

## **Be aware of the X: *BCOR* mutations in myeloid neoplasms**

**Authors:** Guillermo Ramil<sup>1</sup>, Marta Pratcorona<sup>1</sup> and Josep F. Nomdedéu<sup>1\*</sup>

- 1 Department of Hematology. Hospital de la Santa Creu i Sant Pau. Universitat Autònoma de Barcelona and IIB sant Pau. Institut Josep Carreras(IJC). C/ Sant Quintí, 89. 08041 Barcelona. SPAIN.

### **Address correspondence to:**

Josep F. Nomdedéu.  
Servei d'Hematologia  
Hospital de la Santa Creu i Sant Pau  
Universitat Autònoma de Barcelona  
IIB Sant Pau/Institut Josep Carreras  
C/ Sant Quintí, 89  
08041 Barcelona  
Telf:+34-935537378  
jnomdedeu@santpau.cat

In this issue of *Haematologica*, Baranwal et al (1) analyze the clinical and biological features of myeloid neoplasms carrying mutations in the BCL6 Corepressor (*BCOR*) gene.

The introduction of Next-generation Sequencing (NGS) to the diagnosis of myeloid neoplasms such as Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), has shed light on the molecular pathogenesis of these disorders, especially for those cases without recurrent chromosomal alterations. Over the past decade, numerous somatic single-nucleotide variants (SNVs) have been recognized as driver mutations and prognostic biomarkers in myeloid neoplasms (2). This growing evidence has been incorporated into AML and MDS classifications and predictive scores, including new molecularly defined diagnostic categories and several mutations in risk stratification models.

The recent WHO and International Consensus classifications (3,4) have proposed a new group called "AML with myelodysplasia-related gene mutations," defined by somatic mutations in a set of genes, including *BCOR*. This category has also been incorporated in the European LeukemiaNet (ELN) 2022 AML classification (5) within the adverse risk group. On this line, the IPSS-M molecular risk score for MDS has considered *BCOR*, among other genes, a predictor of poor prognosis for MDS patients (6).

BCL6 Corepressor (*BCOR*) is a gene located in chromosome X encoding for a transcriptional repressor that participates in one form of the Polycomb repressive complex 1. This multi-protein complex regulates gene expression through histone modification, and its function is crucial for hematopoiesis and lymphoid differentiation (7). *BCOR* gene alterations have been recurrently found in various human cancers, supporting its role as a tumor suppressor gene (8). In hematologic malignancies, somatic mutations in *BCOR* have been reported in myeloid and lymphoid neoplasms (9,10) and other nonmalignant disorders like aplastic anemia(11).

Baranwal et al (1) sought to characterize *BCOR*-mutated (*mBCOR*) myeloid neoplasms. To investigate their incidence, they screened for *BCOR* mutations through NGS in a consecutive cohort of 6887 adults treated at the Mayo Clinic from 2015 to 2017. They detected 138 (2%) patients carrying any SNV in *BCOR*. The authors describe the clinical features and outcomes of *mBCOR* patients compared to a wild-type cohort and report that *BCOR* mutations are enriched in high-risk MDS and AML with an increasing incidence with age.

Interestingly, *mBCOR* MDS and AML display a distinct genetic signature, with a solid association to *RUNX1* and *U2AF1* mutations and mutual exclusion to other common mutations such as *NPM1* or *TP53*. Regarding cytogenetics, most patients had a normal karyotype, with a minority having complex karyotypes or other high-risk abnormalities. Mutations in *BCOR* were distributed along the coding sequence with no particular hotspot and were mostly frameshift.

The prognosis of *mBCOR* AML and MDS in this study was poor, with a median overall survival of 15 months, irrespective of blast count or their initial diagnosis. While only 52.8% of AML patients in this study were initially assigned to the ELN 20217 adverse risk category, the results of the AML cohort are comparable to the ELN adverse group (5). These data validate the inclusion of *mBCOR* AML into the adverse risk category of the ELN 2022 classification. Patients with complex karyotypes had the worst survival rates, while other co-occurring mutations did not have a substantial negative impact.

The authors demonstrate the beneficial effect of allogeneic stem cell transplant (alloSCT) in this group of myeloid neoplasms, suggesting that all *mBCOR* AML/MDS patients should be evaluated for upfront alloSCT when possible, given that the overall survival rate for alloSCT recipients was 61.1% at three years. Factors worsening post-transplant outcomes in this cohort were *RUNX1* mutations and the presence of complex karyotypes.

The results published in this paper support that *BCOR* mutations identify a high-risk subgroup of myeloid neoplasms with a unique genetic signature and unfavorable prognosis that can be partially modified with alloSCT. Further research is needed to elucidate the impact of *BCOR* mutations on the survival of AML/MDS patients treated with venetoclax-based regimens or other target therapies.

## References:

1. Baranwal A, Gurney M, Basmaci R, Katamesh B, He R, Viswanatha DS, et al. Genetic landscape and clinical outcomes of patients with BCOR mutated myeloid neoplasms. *Haematologica*. xxx
2. Cancer Genome Atlas Research Network; Ley TJ, Miller C, et al. Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia. *N Engl J Med*. 2013;368(22):2059-2074.
3. Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. *Blood*. 2022;140(11):1200-1228.
4. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. *Leukemia*. 2022;36(7):1703-1719.
5. Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. *Blood*. 2022;140(12):1345-1377.
6. Bernard E, Tuechler H, Greenberg PL, et al. Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. *NEJM Evid*. 2022;1(7).
7. Kelly MJ, So J, Rogers AJ, et al. Bcor loss perturbs myeloid differentiation and promotes leukaemogenesis. *Nat Commun*. 2019;10(1):1347.
8. Astolfi A, Fiore M, Melchionda F, Indio V, Bertuccio SN, Pession A. BCOR involvement in cancer. *Epigenomics*. 2019;11(7):835-855.
9. Sportoletti P, Sorcini D, Falini B. BCOR gene alterations in hematologic diseases. *Blood*. 2021;138(24):2455-2468.
10. Damm F, Chesnais V, Nagata Y, et al. BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders. *Blood*. 2023;122(8):3169-1277.
11. Yoshizato T, Dumitriu B, Hosokawa K, et al. Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia. *N Engl J Med*. 2015;373(1):35-47.